Cellular Immunotherapy Market Size & Growth Forecast 2027–2036, By Segments (End-use, Therapy Type, Indication), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape
Market Size and Growth Outlook
Cellular Immunotherapy Market size was valued at USD 15.06 billion in 2026 and is anticipated to grow at a 21.29% CAGR from 2027 to 2036, reaching USD 103.77 billion by 2036. The industry revenue for 2027 is assessed at USD 17.76 billion.
Get more details on this report
Request Free Sample ReportCellular Immunotherapy Market Intelligence Snapshot
Regional Market Dynamics
- North America leads through established treatment infrastructure, specialized oncology centers, strong commercialization of approved therapies, and efficient patient access supporting routine clinical adoption.
- Asia Pacific is projected to grow at a 23.98% CAGR, supported by expanding cancer care capacity, rising therapy adoption, increasing clinical activity, and investment in domestic manufacturing capabilities.
Segment Momentum
- Hospitals lead due to controlled inpatient infrastructure, multidisciplinary clinical teams, and full treatment pathway management from infusion to post-care monitoring, essential for operationally intensive cellular immunotherapy delivery.
- CAR T Cell Therapy leads both largest and fastest-growing adoption due to strong oncology integration and established clinical workflows, supported by expanding specialist expertise and structured treatment environments.
Market Expansion Drivers
- Rising global cancer prevalence accelerating adoption of advanced cellular immunotherapy treatments.
- Expanding clinical trial pipeline and product approvals strengthening commercialization of cell-based therapies.
- Increasing investment in allogeneic off-the-shelf therapies improving scalability of immunotherapy manufacturing.
Leading Market Participants
- Key players in the cellular immunotherapy market include Bristol-Myers Squibb Company (United States), Novartis AG (Switzerland), Gilead Sciences, Inc. (United States), F. Hoffmann-La Roche Ltd (Switzerland), Merck KGaA (Germany), GlaxoSmithKline plc (United Kingdom), AstraZeneca plc (United Kingdom), Pfizer Inc. (United States), Johnson & Johnson (United States), Celyad Oncology SA (Belgium).
Global Market Forecast Snapshot
Market Outlook
- 2026 Market Size: USD 15.06 billion
- 2027 Estimated Market Size: USD 17.76 billion.
- Projected Market Size: USD 103.77 billion by 2036
- Growth Forecast: 21.29% CAGR (2027-2036)
Regional and Segment Outlook
- Leading Regional Market: North America
- High-Growth Regional Hub: Asia Pacific
- Core Revenue Segment: Hospitals (End-use) | CAR T Cell Therapy (Therapy Type) | B-cell Malignancies (Indication)
- Emerging Opportunity Segment: Cancer Institutes (End-use) | CAR T Cell Therapy (Therapy Type) | B-cell Malignancies (Indication)
Market Growth Drivers and Industry Trends
Rising global cancer prevalence accelerating adoption of advanced cellular immunotherapy treatments
The increasing burden of cancer is strengthening demand for innovative treatment approaches, supporting the cellular immunotherapy market as healthcare providers and researchers pursue therapies capable of targeting malignant cells through immune-based mechanisms. Cellular immunotherapies can offer highly specialized treatment approaches by using immune cells that are modified, selected, or expanded to recognize and attack cancer cells, creating opportunities in areas where conventional treatment approaches may have limitations. Growing clinical experience with cell-based therapies is also contributing to greater understanding of patient selection, treatment protocols, manufacturing requirements, and management of therapy-related considerations, supporting broader development across oncology applications.
Expanding clinical trial pipeline and product approvals strengthening commercialization of cell-based therapies
A broader clinical development pipeline is supporting the cellular immunotherapy market by expanding the range of investigational approaches being evaluated across cancer types and treatment settings. Progression from clinical research toward regulatory approvals can strengthen confidence in cell-based therapeutic platforms and encourage healthcare systems to develop the infrastructure required for treatment delivery, including specialized clinical centers, cell processing capabilities, and patient monitoring processes. As more therapies demonstrate clinical utility, developers are gaining opportunities to refine manufacturing workflows and treatment protocols while extending cellular immunotherapy approaches into additional indications and patient populations, increasing the commercial relevance of cell-based treatment platforms.
Increasing investment in allogeneic off-the-shelf therapies improving scalability of immunotherapy manufacturing
Investment in allogeneic cellular therapies is addressing an important scalability consideration within the cellular immunotherapy market by supporting treatment models designed for broader availability rather than relying exclusively on individualized patient-specific manufacturing. Off-the-shelf approaches can simplify production planning and potentially improve consistency by enabling cells to be prepared in advance, subject to appropriate safety, compatibility, and quality requirements. Research and development efforts focused on donor-derived cell sources, cell engineering, cryopreservation, and manufacturing automation are helping advance these platforms, while improvements in production processes can support more standardized handling and distribution of cellular therapy products.
| Growth Driver | Impact on CAGR | Regulatory Influence | Geographic Relevance | Adoption Rate | Impact Timeline |
|---|---|---|---|---|---|
| Rising global cancer prevalence accelerating adoption of advanced cellular immunotherapy treatments | 2.00% | High | North America, Europe | High | Near Term |
| Expanding clinical trial pipeline and product approvals strengthening commercialization of cell-based therapies | 1.90% | High | North America, Asia Pacific | High | Mid Term |
| Increasing investment in allogeneic off-the-shelf therapies improving scalability of immunotherapy manufacturing | 1.60% | High | Europe, North America | Emerging | Long Term |
Unlock insights tailored to your business with our bespoke market research solutions.
Click to get your customized report now.
Regional Demand Dynamics
North America (Largest Region)
North America dominated the cellular immunotherapy market in 2026, supported by advanced healthcare infrastructure, strong oncology research capabilities, and substantial investment in innovative cancer treatments. The region benefits from sophisticated clinical development ecosystems and increasing integration of personalized medicine into cancer care. Continued progress in cell-based therapeutic approaches, specialized treatment facilities, and research-driven healthcare systems is reinforcing regional adoption and supporting the commercialization of advanced immunotherapy solutions.
Asia Pacific (Fastest-Growing Region)
Asia Pacific is positioned as the fastest-growing region, driven by expanding healthcare infrastructure, increasing oncology treatment needs, and growing investment in advanced therapeutic technologies. Improvements in specialized clinical capabilities and greater adoption of personalized treatment approaches are creating favorable conditions for cellular immunotherapy development. Rising healthcare expenditure and efforts to expand access to innovative cancer therapies are further supporting the region's emerging role in this market.
| Parameter | North America | Asia Pacific | Europe | Latin America | MEA |
|---|---|---|---|---|---|
| Innovation Hub i Scale Nascent Developing Advanced | |||||
| Cost-Sensitive Region i Scale Low Medium High | |||||
| Regulatory Environment i Scale Restrictive Neutral Supportive | |||||
| Demand Drivers i Scale Weak Moderate Strong | |||||
| Development Stage i Scale Emerging Developing Developed | |||||
| Adoption Rate i Scale Low Medium High | |||||
| New Entrants / Startups i Scale Sparse Moderate Dense | |||||
| Macro Indicators i Scale Weak Stable Strong |
Key Country Insights
Germany 🇩🇪
Clinical Translation HubGermany's cellular immunotherapy market benefits from strong links between academic research and specialized treatment centers. Stakeholders in Germany are concentrating on integrating innovative cell therapies into clinical practice while strengthening manufacturing capabilities and regulatory readiness for advanced therapeutic products.
France 🇫🇷
Research-Led Treatment IntegrationFrance continues to advance cellular immunotherapy through research institutions and specialized oncology networks. The country's priorities include improving patient access to innovative therapies and expanding clinical capabilities that facilitate the adoption of personalized cell-based treatments across healthcare systems.
Italy 🇮🇹
Specialized Oncology DevelopmentItaly's cellular immunotherapy market is progressing through targeted investments in oncology centers and translational research initiatives. Healthcare institutions in Italy are focusing on strengthening treatment delivery capabilities and fostering collaborations that support the introduction of advanced cell therapies.
Japan 🇯🇵
Precision Cell Therapy AdoptionJapan is emphasizing cellular immunotherapy approaches that align with personalized medicine and regenerative healthcare initiatives. The market in Japan is increasingly focused on streamlining development pathways and supporting collaborations that accelerate the transition of novel therapies into routine clinical settings.
South Korea 🇰🇷
Biomanufacturing Capability ExpansionSouth Korea is investing in manufacturing infrastructure and technology platforms that support cellular immunotherapy development and production. Companies in South Korea are actively pursuing partnerships and contract manufacturing opportunities to strengthen their position within the advanced therapy value chain.
United States 🇺🇸
Commercial Therapy Deployment CenterThe U.S. cellular immunotherapy market is characterized by active commercialization efforts and expanding treatment infrastructure for advanced cell therapies. Healthcare providers and developers in the U.S. are prioritizing manufacturing scalability, patient access pathways, and next-generation therapies targeting broader oncology indications.
Segment Leadership and Growth Trends
Cellular Immunotherapy Market Share (%), by End-use, 2026
Go beyond the chart, access full insights & data tables
Request Free Sample ReportEnd-use Segment Analysis: Hospitals (Largest Segment) vs Cancer Institutes (Fastest-Growing Segment)
The cellular immunotherapy market was led by hospitals in 2026, reflecting their central role in administering advanced immune-based treatments and managing patients requiring complex oncology care. Hospitals typically provide the specialized infrastructure, multidisciplinary expertise, diagnostic capabilities, and monitoring resources needed for cellular immunotherapy, supporting their strong utilization of these therapies. The growing integration of personalized treatment approaches into hospital-based cancer care is further reinforcing demand for sophisticated cellular therapy services.
Cancer institutes are emerging as a rapidly expanding end-use setting as their specialized focus on oncology supports concentrated adoption of advanced cellular immunotherapies. These institutions are well positioned to manage complex treatment pathways, patient selection, intensive monitoring, and specialized post-treatment care. Increasing emphasis on precision oncology and the development of dedicated treatment infrastructure are strengthening the role of cancer institutes in expanding access to cellular immunotherapy.
Therapy Type Segment Analysis: CAR T Cell Therapy (Largest & Fastest-Growing Segment)
CAR T cell therapy held the largest share of the cellular immunotherapy market in 2026 while also representing the fastest-growing therapy type, supported by its highly targeted approach to treating certain cancers. The therapy modifies a patient's immune cells to recognize and attack specific cancer cells, creating strong clinical interest in situations where conventional treatment options may be inadequate. Continued advances in cell engineering, treatment protocols, patient selection, and manufacturing processes are supporting broader adoption and strengthening the position of CAR T cell therapy within cellular immunotherapy.
| Segment | Sub-Segment | Largest Segment | Fastest Growing |
|---|---|---|---|
| End-use | Hospitals, Cancer Institutes, Others | Hospitals | Cancer Institutes |
| Therapy Type | CAR T Cell Therapy, Dendritic Cell Therapy, NK Cell Therapy, TIL Therapy, Others | CAR T Cell Therapy | CAR T Cell Therapy |
| Indication | B-cell Malignancies, Prostate Cancer, Liver Cancer, Renal Cell Carcinoma, Others | B-cell Malignancies | B-cell Malignancies |
Competitive Landscape and Market Positioning
Top players in the cellular immunotherapy market:
1. Bristol-Myers Squibb Company (United States)
2. Novartis AG (Switzerland)
3. Gilead Sciences Inc. (United States)
4. F. Hoffmann-La Roche Ltd (Switzerland)
5. Merck KGaA (Germany)
6. GlaxoSmithKline plc (United Kingdom)
7. AstraZeneca plc (United Kingdom)
8. Pfizer Inc. (United States)
9. Johnson & Johnson (United States)
10. Celyad Oncology SA (Belgium)
Rapid scientific progress is driving the cellular immunotherapy market, with increasing investment in advanced cell engineering, precision therapies, and innovative manufacturing technologies. Ongoing research is expanding treatment possibilities while improving therapeutic effectiveness and scalability.
| Company | Market Share | Company Revenue | Revenue CAGR (%) | Product Portfolio | Geographic Presence | Innovation / R&D Focus | Strategic Developments |
|---|---|---|---|---|---|---|---|
| Bristol-Myers Squibb Company (United States) | |||||||
| Novartis AG (Switzerland) | |||||||
| Gilead Sciences Inc. (United States) | |||||||
| F. Hoffmann-La Roche Ltd (Switzerland) | |||||||
| Merck KGaA (Germany) | |||||||
| GlaxoSmithKline plc (United Kingdom) | |||||||
| AstraZeneca plc (United Kingdom) | |||||||
| Pfizer Inc. (United States) | |||||||
| Johnson & Johnson (United States) | |||||||
| Celyad Oncology SA (Belgium). |
Industry Development/News
| Company Name | Date | Key Development |
|---|---|---|
| UNC | May-26 | Researchers at the University of North Carolina (UNC) developed a next-generation cellular immunotherapy approach targeting acute myeloid leukemia (AML). The new methodology aims to improve both the safety profile and potency of engineered immune cells, addressing critical challenges in current AML treatment landscapes and providing a potential framework for enhanced clinical efficacy in both adult and pediatric patient populations. |
| Gilead Sciences | Apr-26 | Gilead Sciences successfully completed its US$7.8 billion acquisition of Arcellx. By securing full ownership of the investigational BCMA-directed CAR-T therapy anito-cel, Gilead eliminates existing royalty and profit-sharing obligations and integrates Arcellx’s proprietary D-Domain platform into its Kite oncology business, aiming to accelerate the commercialization of next-generation cell therapies for multiple myeloma. |
| Montefiore Einstein | Apr-26 | Montefiore Einstein inaugurated the Manny and Joanne Chirico Cellular Immunotherapy Laboratory. This new facility is designed to bolster translational research infrastructure, specifically accelerating the development and clinical translation of novel cell-based cancer therapies. The investment reflects a strategic commitment to converting academic breakthroughs into scalable, effective immunotherapeutic treatments for complex oncology indications. |
| Xcellbio | Mar-25 | Xcellbio partnered with Royal Perth Hospital to establish an automated manufacturing workflow for tumor-infiltrating lymphocyte (TIL) therapies. By focusing on the standardization and scalability of TIL production—a historically complex process—the collaboration seeks to lower barriers to clinical adoption and facilitate the wider availability of advanced cell-based solid tumor treatments. |
Customize Your Report
Explore examples of how this report can be tailored to different research needs, including custom segments, additional topics or chapters, and related reports. Click a section of the wheel or its numbered marker to explore the available options.
Cellular Immunotherapy Market — Custom Segments
| Segment | Sub-Segment |
|---|---|
| Cell Source | Autologous, Allogeneic, Donor-Derived |
| Manufacturing Model | In-House Manufacturing, Contract Manufacturing, Hybrid Manufacturing |
| Reimbursement Type | Commercially Insured, Government Reimbursed, Self-Pay & Other Funding |
Cellular Immunotherapy Market — Custom TOC
| Custom Chapter | Custom Details |
|---|---|
| Clinical Pipeline and Commercialization Opportunity Assessment |
|
| Treatment Center Readiness and Capacity Mapping |
|
| Reimbursement and Market Access Landscape |
|
Need a different cut of the data?
Request Custom ResearchHow much is the cellular immunotherapy market worth?
How will the cellular immunotherapy industry grow in terms of size and CAGR by 2036?
How are expanding clinical trials and product approvals accelerating commercialization in the cellular immunotherapy market?
Why are investments in allogeneic therapies strategically important for the cellular immunotherapy market?
Why do hospitals hold the largest share in the cellular immunotherapy market?
How is CAR T Cell Therapy driving growth in the cellular immunotherapy market?
What makes North America the largest regional market for cellular immunotherapy?
Why is Asia Pacific the fastest-growing region for the cellular immunotherapy market?
What are the key competitors in the cellular immunotherapy landscape?
Our Clients
"The team took the time to understand our specific business needs and delivered a report that was well aligned with our objectives. Their expertise and understanding of the industry were clearly reflected in the quality and relevance of the insights provided."
Siemens Healthcare
"Our experience in acquiring the research report has been excellent. The depth of analysis, and actionable insights provided have been extremely valuable in supporting our ongoing R&D efforts."
GC Biopharma
"The report offered a comprehensive view of the market trends. The in-depth segmentation and analysis of emerging opportunities gave us a better understanding of the market."
Medtronic
Our Research Team & Methodology
Every Fundamental Business Insights report is built by a dedicated vertical research team, validated through a structured primary-and-secondary methodology, and reviewed for accuracy before it reaches you.
Research Team Overview
Prepared by the Healthcare & Medical Devices Research Team
Delivery
Published
Demand
Available
Support
Trust & Compliance
Research Domains
10 coverage areasResearch Intelligence
| Source | Reference |
|---|---|
| World Health Organization (WHO) | www.who.int |
| U.S. Food & Drug Administration (FDA) | www.fda.gov |
| European Medicines Agency (EMA) | www.ema.europa.eu |
| Centers for Disease Control and Prevention (CDC) | www.cdc.gov |
| National Institutes of Health (NIH) | www.nih.gov |
| National Center for Biotechnology Information (NCBI) | www.ncbi.nlm.nih.gov |
| PubMed | pubmed.ncbi.nlm.nih.gov |
| ClinicalTrials.gov | clinicaltrials.gov |
| International Organization for Standardization (ISO) | www.iso.org |
| ASTM International | www.astm.org |
| Advanced Medical Technology Association (AdvaMed) | www.advamed.org |
| Medical Device Innovation Consortium (MDIC) | mdic.org |
| Biotechnology Innovation Organization (BIO) | www.bio.org |
| International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) | www.ifpma.org |
| U.S. Pharmacopeia (USP) | www.usp.org |
| European Directorate for the Quality of Medicines & HealthCare (EDQM) | www.edqm.eu |
| World Organisation for Animal Health (WOAH) | www.woah.org |
| American Hospital Association (AHA) | www.aha.org |
| OECD Health | www.oecd.org/health |
| World Bank Data | data.worldbank.org |
Research Workflow & Quality Assurance
Data Collection
Verified information gathered through primary and secondary research.
Data Triangulation
Cross-validation using multiple independent data sources.
Forecast Modelling
Market estimates developed using historical trends and analytical models.
Analyst Validation
Findings reviewed by domain experts for accuracy and consistency.
Editorial & Quality Review
Final editorial, quality, and compliance checks before publication.
Final Publication
Released after successful completion of the internal review process.
Report Coverage
📊 Market Assessment
- Market Size & Forecast
- Market Segmentation
- Regional Analysis
- Growth Drivers & Challenges
- Market Dynamics
🏢 Competitive Intelligence
- Competitive Landscape
- Company Profiles
- Competitive Benchmarking
- Mergers & Acquisitions
- Market Share Analysis or Key Company Strategies
🔍 Strategic Analysis
- Value Chain Analysis
- Porter's Five Forces
- PESTLE Analysis
- Pricing Trends
- Supply-Demand Analysis
🚀 Future Outlook
- Technology Landscape
- Regulatory Landscape
- Investment & Funding Landscape
- Emerging Opportunities
- Future Market Outlook
Have a question about this report or need a custom scope?
Request Customization